Variables influencing tumor dosimetry in radioimmunotherapy of CEA- expressing cancers with anti-CEA and antimucin monoclonal antibodies

Journal of Nuclear Medicine

Volumn 38, Issue 3, 1997, Pages 409-418

  Behr, Thomas M ^b   Sharkey, Robert M ^b   Juweid, Malik E ^b   Dunn, Robert M ^b   Ying, Zhiliang ^b   Zhang, Cun H ^b   Siegel, Jeffry A ^b   Goldenberg, David M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

^b NONE

Author keywords

Carcinoembryonic antigen; Monoclonal antibodies; Radioimmunotherapy; Tumor dosimetry

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HMN 14; MONOCLONAL ANTIBODY MN 14; MONOCLONAL ANTIBODY MU 9; MONOCLONAL ANTIBODY NP 4; MUCIN MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER RADIOTHERAPY; COLORECTAL CANCER; DOSIMETRY; DRUG HALF LIFE; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIATION DEPTH DOSE; RADIATION DOSE; RADIOIMMUNOTHERAPY; SOLID TUMOR; THYROID CANCER; TISSUE DISTRIBUTION;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HALF-LIFE; HUMANS; IODINE RADIOISOTOPES; MALE; MANGANESE; MIDDLE AGED; MUCINS; NEPTUNIUM; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE; THYROID NEOPLASMS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0030959805     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet 1995;346:336-340.
2. Goldenberg DM, ed Cancer therapy with radiolabeled antibodies. Boca Raton, FL; CRC Press; 1995.
3. Divgi CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 1995;36:586-592.
4. Blumenthal RD, Sharkey RM, Natale AM, et al. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 1994;54:142-151.
5. 131I-labeled monoclonal antibodies. Cancer Res 1992;52:6036-6044.
6. Mach JP, Carrel S, Merenda C, Heumann D, Roenspies U. In vivo localization of anti-CEA antibody in colon carcinoma. Can results obtained in the nude mice model be extrapolated to the patient situation? Eur J Cancer 1978;(suppl I):113-120.
7. Jain RK. Determination of tumor blood flow: a review. Cancer Res 1988;48: 2641-2658.
8. Hagan PL, Halpem SE, Dillman RO, et al. Tumor size: effect on monoclonal antibody uptake in tumor nodules. J Nucl Med 1986;27:422-427.
9. Williams LE, Duda RB, Proffitt RT, et al. Tumor uptake as a function of tumor mass: a mathematical model. J Nucl Med 1988;29:103-109.
10. Boerman OC, Sharkey RM, Blumenthal RD, Aninipot RL, Goldenberg DM. The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors. Int J Cancer 1992;51:470-475.
11. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144-5153.
12. Behr TM, Sharkey RM, Juweid ME, et al. Factors influencing the pharmacokinetics, dosimetry and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of CEA-expressing tumors. Cancer Res 1996;56:1805-1816.
13. 131I-labeled anti-CEA murine monoclonal antibody IgG. J Nucl Med 1997:in press.
14. 2 anti-CEA monoclonal antibody. J Nucl Med 1996;37:1504-1510.
15. 131I-labeled anti-CEA antibodies: Initial results. J Nucl Med 1996;37 (in press).
16. Sharkey RM, Goldenberg DM, Goldenberg H, et al. Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic, and targeting properties in humans. Cancer Res 1990;50:2823-2831.
17. Sharkey RM, Goldenberg DM, Murthy S, et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 1993;71:2082-2096.
18. Primus FJ, Newell KD, Blue A, Goldenberg DM. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 1983;43:686-692.
19. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55:5935s-5945s.
20. Sharkey RM, Goldenberg DM, Vagg R, et al. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas. Cancer 1994;73:864-877.
21. Wu RK, Siegel JA. Absolute quantitation of radioactivity using the buildup factor. Med Phys 1984;11:189-192.
22. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990; 50:1039s-1042s.
23. Pawlyk DA, Siegel JA, Sharkey RM, Goldenberg DM. Automating large-scale processing of dosimetry data [Abstract]. J Nucl Med 1993;34(suppl):160P.
24. Dunn RM, Juweid ME, Behr TM, Siegel JA, Sharkey RM, Goldenberg DM. An automated internal dosimetry scheme for radiolabeled antibodies. Med Phys 1995;22: 1549-1550.
25. Becker RA, Chambers JM, Wilks AR. The new S language: a program environment for data analysis and graphics. Pacific Grove, CA: Wadsworth and Brooks; 1988.
26. 131I-labeled monoclonal antibody CC49. Cancer Res 1995;55:5881s-5887s.
27. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-941.
28. Murray JL, Mujoo K, Wilmanns C, Mansfield P, Wilbur DS, Rosenblum MG. Variables influencing tumor uptake of anti-melanoma monoclonal antibodies radioiodinated using para-iodobenzoyl (PIB) conjugate. J Nucl Med 1991;32:279-287.
29. Philben VJ, Jakowatz JG, Beatty BG, et al. The effect of tumor CEA content and tumor size in tissue uptake of indium-111-labeled anti-CEA monoclonal antibody. Cancer 1986;57:571-576.
30. Watanabe Y, Endo K, Koizumi M, et al. Effect of tumor mass and antigenic nature on the biodistribution of labeled monoclonal antibodies in mice. Cancer Res 1989;49: 2884-2889.
31. Gallinger S, Reilly RM, Kirsh JC, et al. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 1993;53:271-278.
32. Divgi CR, Scott AM, McDermott K, et al. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. Nucl Med Biol 1994;21:9-15.
33. Thomas GD, Chappell MJ, Dykes PW, et al. Effect of dose, molecular size, affinity, and protein binding on rumor uptake of antibody or ligand: a biomathematical model. Cancer Res 1989;49:3290-3296.
34. Hemando JJ, von Kleist S, Grunert F. A repertoire of monoclonal antibodies reveals extensive epitope heterogeneity in CEA purified from neoplasms originating from different organs. Int J Cancer 1994;56:655-661.
35. Thomas P, Toth CA, Saini KS, Jessup JM, Steele G. The structure, metabolism and function of the carcinoembryonic antigen gene family. Biochim Biophys Acta 1990; 1032:177-189.
36. Bressler EL, Alpern MB, Glazer GM, Francis IR, Ensminger WD. Hypervascular hepatic metastases. Radiology 1987;162:49-51.
37. Goldenberg DM, Sharkey RM, Ford E. Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies. J Nucl Med 1987;28:1604-1610.
38. Pimm MV. Possible consequences of human antibody responses on the biodistribution of fragments of human, humanized or chimeric monoclonal antibodies: a note of caution. Life Sci 1994;55:45-49.
39. Sgouros G. Radioimmunotherapy of micrometastases: side-stepping the solid-tumor hurdle [Editorial]. J Nucl Med 1995;36:1910-1912.
40. Dunn RM, Juweid ME, Behr TM, Siegel JA, Sharkey RM, Goldenberg DM. Dosimetric potential of minimal residual disease using radiolabeled antibodies [Abstract]. J Nucl Med 1996;37(suppl):44P.